IRVINE, Calif. — June 12, 2024 — Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material. TrelCor is an innovative dual-phase bone graft featuring a nanocrystalline hydroxycarbanoapatite (HCA) surface, specially engineered for bone formation.
The study, titled “Characterization of an Advanced Bone Graft Material with a Nanocrystalline Hydroxycarbanoapatite Surface and Dual Phase Composition,” has been published in the Journal of Biomedical Materials Research – Part B: Applied Biomaterials.
Using a variety of analytical techniques, the study confirmed TrelCor’s dual phase composition and a nanostructured HCA surface. Additional testing evaluated various advanced bone graft properties including bioactivity and in vivo stem cell stimulation. The results showed that TrelCor exhibited a robust bioactive response and was capable of stimulating bone forming cells.
“The TrelCor characterization study demonstrated that a bone formation response in synthetic graft materials can be positively impacted by modifying a material’s composition and surface structure,” said Dr. Mark Borden, Ph.D., the study’s lead author and Chief Scientific Officer at Biogennix. “These properties form the foundation of TrelCor’s advanced technology, found in Biogennix’s entire line of bone graft products.”
The study’s findings underscore TrelCor’s efficacy in actively stimulating a bone formation response, which leads it to significantly outperforming traditional, first generation bone graft materials. With over 75,000 successful implantations, TrelCor has been a preferred choice for surgeons looking for a reliable, effective, advanced technology bone regeneration solution. This study further reinforces TrelCor’s market positioning and supports its standing as a truly advanced bone graft technology.
Biogennix designs, manufactures, and distributes all of its products from its state-of-the-art facilities in Irvine, California, ensuring the highest standards of quality and safety.
To access the peer-reviewed TrelCor study, click HERE.
For additional information about Biogennix and TrelCor, visit biogennix.com.
About Biogennix:
Biogennix is a pioneering osteobiologics company based in Irvine, California, committed to developing, manufacturing, and distributing advanced bone grafting products for bone fusion procedures. Its focus on innovation, quality, and customer satisfaction continues to set it apart as a leader in the medical device industry.
“TrelCor” is a registered trademark of Biogennix.
Media Contact:
Paul Williams
(310) 569-0023
[email protected]